NasdaqGS - Nasdaq Real Time Price USD

Xeris Biopharma Holdings, Inc. (XERS)

Compare
4.9400
-0.2100
(-4.08%)
As of 12:22:55 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
203,070
203,070
163,914
110,248
49,590
Cost of Revenue
36,832
36,832
28,645
22,634
13,318
Gross Profit
166,238
166,238
135,269
87,614
36,272
Operating Expense
199,884
199,884
179,279
169,554
151,428
Operating Income
-33,646
-33,646
-44,010
-81,940
-115,156
Net Non Operating Interest Income Expense
-27,854
-27,854
-21,858
-11,524
-6,867
Other Income Expense
4,396
4,396
2,364
-2,620
-702
Pretax Income
-57,104
-57,104
-63,504
-96,084
-122,725
Tax Provision
-2,268
-2,268
-1,249
-1,424
--
Net Income Common Stockholders
-54,836
-54,836
-62,255
-94,660
-122,725
Diluted NI Available to Com Stockholders
-54,836
-54,836
-62,255
-94,660
-122,725
Basic EPS
-0.43
-0.37
-0.45
-0.70
-1.55
Diluted EPS
-0.43
-0.37
-0.45
-0.70
-1.55
Basic Average Shares
144,004.1040
146,772.7580
137,674.8570
135,628.7210
79,027.0620
Diluted Average Shares
144,004.1040
146,772.7580
137,674.8570
135,628.7210
79,027.0620
Total Operating Income as Reported
-33,646
-33,646
-44,010
-81,940
-115,156
Total Expenses
236,716
236,716
207,924
192,188
164,746
Net Income from Continuing & Discontinued Operation
-54,836
-54,836
-62,255
-94,660
-122,725
Normalized Income
-59,057.4040
-59,057.4040
-64,572.5047
-92,078.8294
-122,023
Interest Income
5,321
5,321
4,751
2,578
313
Interest Expense
30,485
30,485
26,609
14,102
7,180
Net Interest Income
-27,854
-27,854
-21,858
-11,524
-6,867
EBIT
-26,619
-26,619
-36,895
-81,982
-115,545
EBITDA
-13,994
-13,994
-23,735
-69,314
-113,666
Reconciled Cost of Revenue
35,050
35,050
26,328
20,809
11,989
Reconciled Depreciation
12,625
12,625
13,160
12,668
1,879
Net Income from Continuing Operation Net Minority Interest
-54,836
-54,836
-62,255
-94,660
-122,725
Total Unusual Items Excluding Goodwill
4,396
4,396
2,364
-2,620
-702
Total Unusual Items
4,396
4,396
2,364
-2,620
-702
Normalized EBITDA
-18,390
-18,390
-26,099
-66,694
-112,964
Tax Rate for Calcs
0
0
0
0
--
Tax Effect of Unusual Items
174.5960
174.5960
46.4953
-38.8294
--
12/31/2021 - 6/21/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MREO Mereo BioPharma Group plc
2.3150
-2.32%
 
RCKT Rocket Pharmaceuticals, Inc.
5.76
-8.56%
 
ADMA ADMA Biologics, Inc.
19.48
-3.71%
 
SGMO Sangamo Therapeutics, Inc.
0.5964
-8.70%
 
ARDX Ardelyx, Inc.
4.6092
-5.55%
 
TGTX TG Therapeutics, Inc.
39.87
+0.13%
 
HUMA Humacyte, Inc.
1.4550
-0.34%
 
CAPR Capricor Therapeutics, Inc.
9.25
-5.08%
 
AUPH Aurinia Pharmaceuticals Inc.
8.00
-2.32%
 
SVRA Savara Inc.
2.9500
-1.99%